BVF Inc. IL Has $37.07 Million Stake in AC Immune $ACIU

Key Points

• BVF Inc. IL increased its stake in AC Immune by 1.5%, purchasing an additional 300,000 shares, bringing its total to nearly 19.82 million shares, which is approximately 19.74% of the company's ownership.
• AC Immune had a negative earnings report, posting a loss of ($0.25) EPS for the last quarter, missing analysts' expectations and indicating a negative net margin of 174.94%.
• The stock has recently received an upgrade from a "hold" to a "buy" rating by analysts, with a consensus target price of $12.00, despite its current trading value around $2.21.

BVF Inc. IL increased its position in AC Immune (NASDAQ:ACIU - Free Report) by 1.5% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 19,822,436 shares of the company's stock after acquiring an additional 300,000 shares during the quarter. AC Immune comprises about 1.5% of BVF Inc. IL's investment portfolio, making the stock its 13th biggest position. BVF Inc. IL owned about 19.74% of AC Immune worth $37,068,000 at the end of the most recent reporting period.

Several other institutional investors have also recently bought and sold shares of the company. Banque Cantonale Vaudoise bought a new position in AC Immune in the 1st quarter worth $50,000. Squarepoint Ops LLC acquired a new stake in AC Immune in the 4th quarter worth $118,000. Two Sigma Advisers LP acquired a new stake in AC Immune in the 4th quarter worth $36,000. Cantor Fitzgerald L. P. acquired a new stake in AC Immune in the 4th quarter worth $68,000. Finally, Jane Street Group LLC acquired a new stake in AC Immune in the 4th quarter worth $66,000. Institutional investors own 51.36% of the company's stock.

AC Immune Stock Up 6.0%

NASDAQ:ACIU traded up $0.13 on Friday, reaching $2.28. The stock had a trading volume of 244,247 shares, compared to its average volume of 110,521. The company has a market capitalization of $228.93 million, a P/E ratio of -3.93 and a beta of 1.61. AC Immune has a 1-year low of $1.43 and a 1-year high of $3.98. The stock has a fifty day moving average price of $2.14 and a 200-day moving average price of $1.98.

AC Immune (NASDAQ:ACIU - Get Free Report) last announced its earnings results on Tuesday, August 5th. The company reported ($0.25) earnings per share for the quarter, missing analysts' consensus estimates of ($0.20) by ($0.05). AC Immune had a negative return on equity of 49.35% and a negative net margin of 174.94%.The company had revenue of $1.65 million during the quarter, compared to the consensus estimate of $1.98 million. Sell-side analysts predict that AC Immune will post -0.62 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, Wall Street Zen upgraded shares of AC Immune from a "hold" rating to a "buy" rating in a research report on Tuesday, May 13th. One equities research analyst has rated the stock with a Buy rating, Based on data from MarketBeat, AC Immune has a consensus rating of "Buy" and an average price target of $12.00.

About AC Immune

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.